SK15002000A3 - Oxazolchinolónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie na inhibíciu mrp1 u cicavcov - Google Patents

Oxazolchinolónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie na inhibíciu mrp1 u cicavcov Download PDF

Info

Publication number
SK15002000A3
SK15002000A3 SK1500-2000A SK15002000A SK15002000A3 SK 15002000 A3 SK15002000 A3 SK 15002000A3 SK 15002000 A SK15002000 A SK 15002000A SK 15002000 A3 SK15002000 A3 SK 15002000A3
Authority
SK
Slovakia
Prior art keywords
alkyl
substituted
heterocycle
following groups
compound
Prior art date
Application number
SK1500-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Joseph Michael Gruber
Bryan Hurst Norman
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SK15002000A3 publication Critical patent/SK15002000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1500-2000A 1998-04-08 1999-04-07 Oxazolchinolónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie na inhibíciu mrp1 u cicavcov SK15002000A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8107798P 1998-04-08 1998-04-08
PCT/US1999/007343 WO1999051227A1 (fr) 1998-04-08 1999-04-07 Procedes d'inhibition de mrp1

Publications (1)

Publication Number Publication Date
SK15002000A3 true SK15002000A3 (sk) 2001-06-11

Family

ID=22161958

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1500-2000A SK15002000A3 (sk) 1998-04-08 1999-04-07 Oxazolchinolónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie na inhibíciu mrp1 u cicavcov

Country Status (17)

Country Link
US (1) US6417193B1 (fr)
EP (1) EP1069897A1 (fr)
JP (1) JP2002510624A (fr)
KR (1) KR20010042482A (fr)
CN (1) CN1296408A (fr)
AU (1) AU3468099A (fr)
BR (1) BR9909497A (fr)
CA (1) CA2327706A1 (fr)
EA (1) EA200001036A1 (fr)
HU (1) HUP0101736A3 (fr)
ID (1) ID27048A (fr)
IL (1) IL138391A0 (fr)
NO (1) NO20005042D0 (fr)
PL (1) PL343312A1 (fr)
SK (1) SK15002000A3 (fr)
TR (1) TR200002803T2 (fr)
WO (1) WO1999051227A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233487T3 (es) * 1999-12-22 2005-06-16 Eli Lilly And Company Procedimientos y compuestos para la inhibicion de mrp1.
US6743794B2 (en) 1999-12-22 2004-06-01 Eli Lilly And Company Methods and compounds for inhibiting MRP1
CA2411813A1 (fr) 2000-06-14 2001-12-20 Eli Lilly And Company Composes tricycliques utilises comme inhibiteurs de mrp1
EP1296953A2 (fr) * 2000-06-23 2003-04-02 Eli Lilly And Company Procedes et composes d'inhibition du mrp1
JP2004509897A (ja) * 2000-09-22 2004-04-02 イーライ・リリー・アンド・カンパニー シクロヘキシルアミン誘導体の立体選択的製造方法
DE60207709T2 (de) 2001-04-09 2006-07-20 Eli Lilly And Co., Indianapolis Verbindungen und methoden zur inhibierung von mrp1
CN1281210C (zh) * 2003-11-29 2006-10-25 胡汛 五味子乙素在制备治疗肿瘤药物中的应用
CN104002843A (zh) * 2014-05-29 2014-08-27 安徽银龙泵阀股份有限公司 一种减震效果好易于放置的双泵移动车

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744485A (en) 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity

Also Published As

Publication number Publication date
US6417193B1 (en) 2002-07-09
KR20010042482A (ko) 2001-05-25
WO1999051227A1 (fr) 1999-10-14
PL343312A1 (en) 2001-08-13
CN1296408A (zh) 2001-05-23
TR200002803T2 (tr) 2000-12-21
BR9909497A (pt) 2000-12-12
JP2002510624A (ja) 2002-04-09
IL138391A0 (en) 2001-10-31
ID27048A (id) 2001-02-22
EA200001036A1 (ru) 2001-04-23
HUP0101736A2 (hu) 2001-11-28
HUP0101736A3 (en) 2002-04-29
NO20005042L (no) 2000-10-06
AU3468099A (en) 1999-10-25
EP1069897A1 (fr) 2001-01-24
CA2327706A1 (fr) 1999-10-14
NO20005042D0 (no) 2000-10-06

Similar Documents

Publication Publication Date Title
JP6896113B2 (ja) ジアザ二環式置換イミダゾピリミジンおよび呼吸障害を治療するためのその使用
EP1341759B1 (fr) Agonistes du recepteur beta-3 d'oxindole 3-substitue
KR100312444B1 (ko) 트리플루오로메틸피롤로인돌카르복실산에스테르유도체및그의제조방법
EP2842956A1 (fr) Composés inhibiteurs de la PARP, compositions et procédés d'utilisation
SK822002A3 (en) New compounds
EP1212325A2 (fr) Nouvelle forme cristalline de disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo 2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l- sel d'acide glutamique et procedes de preparation
AU2011280297A1 (en) Cyclic N,N'-diarylthioureas and N,N'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
KR100687165B1 (ko) 결정성 2,5-디온-3-(1-메틸-1ｈ-인돌-3-일)-4-[1-[1-(피리딘-2-일메틸)피페리딘-4-일]-1ｈ-인돌-3-일]-1ｈ-피롤 모노-하이드로클로라이드
SK15002000A3 (sk) Oxazolchinolónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie na inhibíciu mrp1 u cicavcov
US6369070B1 (en) Methods for inhibiting mrp1
US20220098201A1 (en) The monohydrate of rogaratinib hydrochloride and solid states thereof
SK14992000A3 (sk) Spôsob inhibície mrpi
TW201136925A (en) Triazole compounds as KSP inhibitors
CZ20003688A3 (cs) Způsob inhibice MRP1
MXPA00009825A (en) Methods for inhibiting mrp1
CN110885316B (zh) 作为组蛋白去乙酰化酶抑制剂的巯基化合物及其用途
WO2023204303A1 (fr) Cristal de dérivé de 7h-pyrrolo[2,3-d]pyrimidine-4-amine
US20040116460A1 (en) Compounds and pharmaceutical compositions for inhibiting mrp1
CZ20003689A3 (cs) Způsob inhibice MRP1
CZ20003687A3 (cs) Způsoby inhibice MRP1
JPH0834788A (ja) ピロロベンゾカルバゾール誘導体及びその製造方法
JPH06122684A (ja) ピロロインドールジカルボン酸ジエステル誘導体及びその製造方法
JPH0211568A (ja) ２―ピリジル酢酸誘導体
JP2004529919A (ja) Ｍｒｐ１を阻害するための化合物および方法